SSX-4 peptides presented by HLA class II molecules

Details SSX-4 peptides presented by HLA class II molecules SSX-4 peptides presented by HLA class II molecules

2011-08-30

2011-08-30

Huff, Sheela J (Department: 1643)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S320100

Reexamination Certificate

active

08008464

ABSTRACT:
The invention describes HLA class II binding peptides encoded by the SSX-4 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the SSX-4 gene.

REFERENCES:
patent: 5965535 (1999-10-01), Chaux et al.
patent: 6291658 (2001-09-01), Gure et al.
patent: 6548064 (2003-04-01), Tureci et al.
patent: 50528 (1998-11-01), None
patent: WO 02081646 (2002-10-01), None
Ayyoub, Maha, et al., CD4+ T Cell responses to SSX-4 in Melanoma Patients,The Journal of Immunology, Copyright 2005, The American Association of Immunologies, Inc., pp. 5092-5099.
Ayyoub, M. et al. 2004, An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR,J Clin Invest113: 1225-33.
Ayyoub, M et al., 2004, Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells,J. Immunol172:7206-7211.
Ayyoub, M. et al., 2002, Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastic melanoma,J Immunol, 168:1717-1722.
Ayyoub, M. et al., 2003, SSX antigens as tumor vaccine targets in human sarcoma,Cancer Immunity, 3:13.
Ayyoub, M. et al., 2003, Tumor-reactive SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen expressing tumors in melanoma patients,Cancer Res, 63:5601-5606.
Ayyoub, M. et al., 2005, CD4+T cell responses to SSX-4 in melanoma patients,J Immunol, 174:5092-5099.
Brodin, B. et al., 2001, Cloning and characterization of spliced fusion transcript variants of synovial sarcoma: SYT/SSX4, SYT/SSX4v, and SYT/SSX2v. Possible regulatory role of the fusion gene product in wild type SYT expression,Gene, 268: 173-182.
Chaux, P. et al., 1999, Identification of MAGE-3 epitopes presented by HLA-DR molecules to cd4(+) T Lymphocytes,J Exp Med, 189:767-778.
Chen L. P. et al., 1991, Human Papillomavirus Type 16 Nucleoprotein E7 is a Tumor Rejection Antigen,Proc. Natl. Acad. Sci USA88: 110-114.
Chen, C.H. et al., 2001, Expressions of cancer-testis antigens in human hepatocellular carcinomas,Cancer Left, 164: 189-195.
Chicz, R.M. et al., 1993, Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles,J. Exp. Med. 178:27-47.
Coulie; P.G. 1995, Antigens recognized on human tumors by cytolytic T lymphocytes; towards vaccination?Stem Cells, 13(4):393-403.
Crew, A.J. et al., 1995, Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma,Embo J, 14:2333-2340.
De Smet, C. et al., 1996, The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation,Proc Natl Acad Sci U S A, 93:7149-7153.
De Smet, C. et al., 2004, Promoter=dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells,Mol Cell Biol, 24(11):4781-4790.
Demoulin, J.B. et al., 1996, A single tyrosine of the interleukin-9 (IL-9) receptor is required for the STAT activation, antiapoptotic activity, and growth regulation by IL-9,Mol. Cell, Biol. 16(9):4710-4716.
Dos Santos, N.R. et al., 1997, Nuclear Localization of SYT , SSX and the synovial sarcoma-associated SYT-SSX fusion proteins,Hum Mol Genet, 6(9):1549-1558.
Dos Santos, N.R. et al., 2000, Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines,Cancer Res, 60:1654-1662.
Drakesmith, H. et al., 1998, In vivo priming of T cells against cryptic determinants by dendritic cells exposed to interleukin 6 and native antigen,Proc Natl Acad U S A, 95: 14903-14908.
Engelhard., V.H., 1994, Structure of peptides associated with class I and class II MHC molecules.Annu. Rev. Immunol, 12:181-201.
Gaschet, J. et al., 1996 Acute graft versus host disease due to T lymphocytes recognizing a single HLA-DPB1*0501 mismatch,J Clin Invest, 98:100-107.
Gilbert, S.C. et al., 1997, A protein particle vaccine containing multiple malaria epitomes,Natural Biotechnol. 15:1280-1284.
Gure, A.O. et al., 1997, SSX a multigene family with several members transcribed in normal testis and human cancer,Int J Cancer, 72:956-971.
Gure, A.O. et al., 2002, The SSX Gene Family: Characterization of 9 complete genes,Int J Cancer, 101:448-453.
Halder, T. et al., 1997, Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3,Cancer Res, 57:3238-3244.
Hung, K. et al., 1998, The central role of CD4(+) T cells in the Antitumor Immune Response,J. Exp. Med. 188(12):2357-2368.
James, R.F. et al., 1991, The effect of class II gene transfection on the tumourigenicity of the H-2K-negative mouse leukaemia cell line K36.16,Immunology, 72:213-218.
Kersh, G.J. et al., 2001, Structural and functional consequences of altering a peptide MGC anchor residue,Journal of Immunology, vol. 166, pp. 3345-3354.
Klebanoff, C.A. et al., 2004, IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells,Proc. Natl. Acad. Sci. USA101(7):1969-74.
Klenerman, P. et al., 2002, Tracking T cells with tetramers; new tales from new tools,Nat Rev Iummunol, 2:263-272.
Kocher, T. et al., 1995, Identification and intracellular location of MAGE-3 gene product,Cancer Res, 55:2236-2239.
Li, Y. et al., 2006, Mutational analysis of the binding of staphylococcal enterotoxin D to the T cell receptor VB chain and major histocompatibility complex class II,Immunology Letters, vol. 105, pp. 55-60.
Lim, F.L. et al., 1998, A KRAB-related domain and a novel transcription repression domain in proteins encoded by SSX genes that are disrupted in human sarcomas,Oncogene, 17:2013-2018.
Margolin, J.F. et al., 1994, Kruppel-associated boxes are potent transcriptional repression domains,Proc Natl Acad Sci U S A, 91:4509-4513.
Mizushima, S. and Nagata, S., 1990, pEF-BOS, a powerful mammalian expression vector.Nucleic Acids Res, 18(17):5322.
Moosmann, P. et al., 1996, Transcriptional repression by RING finger protein TIF1 beta that interacts with the KRAB repressor domain of KOX1,Nucleic Acids Res., 24:4859-4867.
Mumberg, D. et al., 1999, CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma,Proc Natl Acad Sci U S A, 96; 8633-8638.
Murray K.J. et al., 1999, Age-specific effects of juvenile rheumatoid arthritis-associated HLA alleles,Arthritis Rheum, 42(9):1843-53.
Naka, N. et al., 2002, Expression of SSX genes in human osteosarcomas,Int J Cancer, 98:640-642.
Nanda, N.K and Sant, A.J., 2000, DM determines the cryptic and immunodominant fate of T cell epitopes,J Exp Med, 192(6):781-788.
Pieper, R. et al., 1999, Biochemical identification of mutated human melanoma antigen recognized by CD4(+)T cells,J Exp Med, 189(5):757-765.
Qin, Z. and Blankenstein, T., 2000, CD4+ T Cells—mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells,Immunity, 12:677-686.
Rammensee H-G. et al., 1995, MHC ligands and peptide motifs: first listing,Immunogenetics, 41:178-228.
Rubio-Godoy, V. et al., 2002, Combinatorial peptide library-based identification of peptide ligands for tumor reactive cytolytic T lymphocytes of unknown specificity,Eur Immunol, 32:2292-2299.
Sanderson, S. et al., 1995, Expression of Endogenous peptide-Major Histocompatibility Complex Class II Complexes derived from Invariant Chain-Antigen Fusion Proteins,Proc. Nat'l. Acad. Sci USA92:7217-7221.
Scanlan, M.J. et al., 2002, Cancer/testis antigens: an expanding family of targets for cancer immunotherapy,Immunol Rev, 188:22-32.
Schultz, E.S. et al., 2000, A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes,Cancer Res, 60:6272-6275.
Stratford-Perricaudet, L.D. et al., 1992, Widespread long-term gene transfer to mouse skeletal muscles and heart,J. Clin. Invest. 90:626-630.
Sturniolo, T. et al., 1999, Generation of tissue-specific and p

Affiliated with

Also associated with

Rating

SSX-4 peptides presented by HLA class II molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with SSX-4 peptides presented by HLA class II molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and SSX-4 peptides presented by HLA class II molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2778221